A novel GLUD1 mutation (N410I) causes HI/HA syndrome, which responds to diazoxide for hypoglycemia but may still be associated with severe neurodevelopmental deficits.
Answers are grounded in this paper and cite their sources.
Neurodevelopmental deficits may persist despite diazoxide control of hypoglycemia in HI/HA; leaves open whether early intervention modifies outcomes in novel GLUD1 mutations.
Hyperinsulinism-hyperammonemia (HI/HA) syndrome, often characterized by recurrent symptomatic hypoglycemia and persistent hyperammonemia, is the second most frequent cause of the congenital hyperinsulinism (CHI). Here, we reported a patient with normal birth weight, repeated seizures, untreatable hypoglycemia, and persistent, mild hyperammonemia. The genetic diagnosis revealed that the patient carried a heterozygous, de novo missense mutation (N410I, c.1401A>T) in the glutamate dehydrogenase 1 gene (GLUD1). The patient was treated with diazoxide, which significantly alleviated the hypoglycemia. CT and MRI brain scanning at different developmental stages revealed large-scale brain damage in the front lobe. Severe neurodevelopment deficits were identified in the follow-up.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: